Clinical Trials Logo

Androgen Antagonists clinical trials

View clinical trials related to Androgen Antagonists.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03080116 Recruiting - Prostate Cancer Clinical Trials

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

ARNEO
Start date: March 28, 2019
Phase: Phase 2
Study type: Interventional

RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy without a survival benefit. There is no evidence yet of a survival impact of LHRH antagonist (LHRHa) +/- new-generation anti-androgens in this setting. Thus novel studies are needed to assess this treatment combination. PURPOSE: To assess the difference in treatment antitumor effect between arms by measuring pathological tumor volume with minimal residual disease (MRD) following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for intermediate or high-risk prostate cancer patients.